Journal of Renal Nutrition
Volume 20, Issue 4 , Pages 243-254 , July 2010

Association of Relatively Low Serum Parathyroid Hormone With Malnutrition-Inflammation Complex and Survival in Maintenance Hemodialysis Patients

  • Ramanath Dukkipati, MD

      Affiliations

    • Harold Simmons Center for Chronic Disease Research and Epidemiology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90502
    • ,
  • Csaba P. Kovesdy, MD

      Affiliations

    • Salem Veteran Affairs Medical Center, Salem, VA 24153
    • ,
  • Sara Colman, RD

      Affiliations

    • DaVita, El Segundo, CA 90245
    • ,
  • Matthew J. Budoff, MD

      Affiliations

    • Division of Cardiology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90502
    • David Geffen UCLA School of Medicine, Los Angeles, CA 90095
    • ,
  • Allen R. Nissenson, MD

      Affiliations

    • DaVita, El Segundo, CA 90245
    • David Geffen UCLA School of Medicine, Los Angeles, CA 90095
    • ,
  • Stuart M. Sprague, DO

      Affiliations

    • Northwestern University Feinberg School of Medicine, Evanston Northwestern Healthcare, Evanston, IL 60201
    • ,
  • Joel D. Kopple, MD

      Affiliations

    • Harold Simmons Center for Chronic Disease Research and Epidemiology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90502
    • ,
  • Kamyar Kalantar-Zadeh, MD, MPH, PhD

      Affiliations

    • Harold Simmons Center for Chronic Disease Research and Epidemiology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90502
    • Corresponding Author InformationAddress reprint requests to Kamyar Kalantar-Zadeh, MD, PhD, MPH, Harold Simmons Center for Kidney Disease Research and Epidemiology, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, 1124 West Carson Street, C1-Annex, Torrance, CA 90502.

References 

  1. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69:1945–1953
  2. Martin KJ, Olgaard K, Coburn JW, et al. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis. 2004;43:558–565
  3. Wolf M, Thadhani R. Vitamin D in patients with renal failure: a summary of observational mortality studies and steps moving forward. J Steroid Biochem Mol Biol. 2007;103:487–490
  4. Gal-Moscovici A, Sprague SM. Role of vitamin D deficiency in chronic kidney disease. J Bone Miner Res. 2007;22(suppl 2):V91–V94
  5. Coen G. Adynamic bone disease: an update and overview. J Nephrol. 2005;18:117–122
  6. Mucsi I, Hercz G. Adynamic bone disease: pathogenesis, diagnosis and clinical relevance. Curr Opin Nephrol Hypertens. 1997;6:356–361
  7. Haris A, Sherrard DJ, Hercz G. Reversal of adynamic bone disease by lowering of dialysate calcium. Kidney Int. 2006;70:931–937
  8. Sanchez CP. Adynamic bone revisited: is there progress?. Perit Dial Int. 2006;26:43–48
  9. Kovesdy CP, Kalantar-Zadeh K. Bone and mineral disorders in pre-dialysis CKD. Int Urol Nephrol. 2008;40:427–440
  10. Kovesdy CP, Ahmadzadeh S, Anderson JE, et al. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int. 2008;73:1296–1302
  11. Kovesdy CP, Ahmadzadeh S, Anderson JE, et al. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med. 2008;168:397–403
  12. National Kidney Foundation . Kidney Disease-Dialysis Outcome Quality Initiative: K/DOQI Clinical Practice Guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42:S1–S202
  13. Kovesdy CP, Mehrotra R, Kalantar-Zadeh K. Battleground: chronic kidney disorders mineral and bone disease: calcium obsession, vitamin D, and binder confusion. Clin J Am Soc Nephrol. 2008;3:168–173
  14. Melamed ML, Eustace JA, Plantinga LC, et al. Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: the CHOICE study. Nephrol Dial Transplant. 2008;23:1650–1658
  15. Andress DL, Coyne DW, Kalantar-Zadeh K, et al. Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. Endocr Pract. 2008;14:18–27
  16. Kalantar-Zadeh K, Duong U, Dukkipati R, et al. Kidney bone disease and mortality in CKD: the role of vitamin D, alkaline phosphatase and minerals. Kidney Int Suppl. 2009;in press
  17. Kalantar-Zadeh K, Kovesdy C, Kopple J: Inflammation in renal insufficiency, in UpToDate, edited by Rose B, Waltham, MA, 2008
  18. Fouque D, Kalantar-Zadeh K, Kopple J, et al. A proposed nomenclature and diagnostic criteria for protein-energy wasting in acute and chronic kidney disease. Kidney Int. 2008;73:391–398
  19. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70:771–780
  20. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–2218
  21. Kestenbaum B, Andress DL, Schwartz SM, et al. Survival following parathyroidectomy among United States dialysis patients. Kidney Int. 2004;66:2010–2016
  22. Nakai S, Akiba T, Kazama J, et al. Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan. Ther Apher Dial. 2008;12:49–54
  23. Kovesdy CP, Kalantar-Zadeh K. Vitamin D receptor activation and survival in chronic kidney disease. Kidney Int. 2008;73:1355–1363
  24. Dobrez DG, Mathes A, Amdahl M, et al. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings. Nephrol Dial Transplant. 2004;19:1174–1181
  25. Shantouf R, Budoff MJ, Ahmadi N, et al. Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients. Am J Nephrol. 2008;28:275–279
  26. Kalantar-Zadeh K, Brennan ML, Hazen SL. Serum myeloperoxidase and mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2006;48:59–68
  27. Kalantar-Zadeh K, Kopple JD, Kamranpour N, et al. HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int. 2007;72:1149–1156
  28. Rambod M, Kovesdy CP, Kalantar-Zadeh K. Combined high serum ferritin and low iron saturation in hemodialysis patients: the role of inflammation. Clin J Am Soc Nephrol. 2008;3:1691–1701
  29. Bross R, Zitterkoph J, Pithia J, et al. Association of serum total iron-binding capacity and its changes over time with nutritional and clinical outcomes in hemodialysis patients. Am J Nephrol. 2009;29:571–581
  30. Rambod M, Bross R, Zitterkoph J, et al. Association of malnutrition-inflammation score with quality of life and mortality in hemodialysis patients: a 5-year prospective cohort study. Am J Kidney Dis. 2009;53:298–309
  31. Rambod M, Kovesdy CP, Bross R, et al. Association of serum prealbumin and its changes over time with clinical outcomes and survival in patients receiving hemodialysis. Am J Clin Nutr. 2008;88:1485–1494
  32. Colman S, Bross R, Benner D, et al. The Nutritional and Inflammatory Evaluation in Dialysis patients (NIED) study: overview of the NIED study and the role of dietitians. J Ren Nutr. 2005;15:231–243
  33. Fried L, Bernardini J, Piraino B. Charlson comorbidity index as a predictor of outcomes in incident peritoneal dialysis patients. Am J Kidney Dis. 2001;37:337–342
  34. Beddhu S, Bruns FJ, Saul M, et al. A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. Am J Med. 2000;108:609–613
  35. Nelson EE, Hong CD, Pesce AL, et al. Anthropometric norms for the dialysis population. Am J Kidney Dis. 1990;16:32–37
  36. Williams AJ, McArley A. Body composition, treatment time, and outcome in hemodialysis patients. J Ren Nutr. 1999;9:157–162
  37. Kalantar-Zadeh K, Kopple JD, Block G, et al. A malnutrition-inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2001;38:1251–1263
  38. Kalantar-Zadeh K, Dunne E, Nixon K, et al. Near infra-red interactance for nutritional assessment of dialysis patients. Nephrol Dial Transplant. 1999;14:169–175
  39. Kalantar-Zadeh K, Kuwae N, Wu DY, et al. Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am J Clin Nutr. 2006;83:202–210
  40. Budoff MJ, Shaw LJ, Liu ST, et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol. 2007;49:1860–1870
  41. Basiotis PP, Welsh SO, Cronin FJ, et al. Number of days of food intake records required to estimate individual and group nutrient intakes with defined confidence. J Nutr. 1987;117:1638–1641
  42. Nussbaum SR, Zahradnik RJ, Lavigne JR, et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem. 1987;33:1364–1367
  43. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–1565
  44. Erbagci AB, Tarakcioglu M, Aksoy M, et al. Diagnostic value of CRP and Lp(a) in coronary heart disease. Acta Cardiol. 2002;57:197–204
  45. Pecoits-Filho R, Barany P, Lindholm B, et al. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant. 2002;17:1684–1688
  46. Stenvinkel P, Heimburger O, Jogestrand T. Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity. Am J Kidney Dis. 2002;39:274–282
  47. Beutler B, Cerami A. The biology of cachectin/TNF - a primary mediator of host response. Annu Rev Immunol. 1989;7:625–655
  48. Barreto FC, Barreto DV, Moyses RM, et al. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int. 2008;73:771–777
  49. Kalantar-Zadeh K, Kopple JD. Response to ‘Adynamic Bone Disease and MICS.’. Kidney Int. 2007;71:1327;[letter reply]
  50. Sanchez-Gonzalez MC, Lopez-Barea F, Bajo MA, et al. Serum albumin levels, an additional factor implicated in hyperparathyroidism outcome in peritoneal dialysis: a prospective study with paired bone biopsies. Adv Perit Dial. 2006;22:198–202
  51. Carlstedt E, Ridefelt P, Lind L, et al. Interleukin-6 induced suppression of bovine parathyroid hormone secretion. Biosci Rep. 1999;19:35–42
  52. Bologa RM, Levine DM, Parker TS, et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis. 1998;32:107–114
  53. Nielsen PK, Rasmussen AK, Butters R, et al. Inhibition of PTH secretion by interleukin-1 beta in bovine parathyroid glands in vitro is associated with an up-regulation of the calcium-sensing receptor mRNA. Biochem Biophys Res Commun. 1997;238:880–885
  54. Akizawa T, Kinugasa E, Kurihara R, et al. Risk factors for the development of parathyroid hormone deficiency in dialysis patients. J Am Soc Nephrol. 1998;9:561A
  55. Avram M, Sreedhara R, Oo K, et al. Prognostic value of enrollment nutritional markers including novel predictors PTH and prealbumin in hemodialysis patients: 12 years of follow-up. J Am Soc Nephrol. 1999;10:272A
  56. Avram M, Sreedhara R, Henry A, et al. Correlates of survival in peritoneal dialysis: 15 years of follow-up. J Am Soc Nephrol. 1999;10:311A
  57. Fukagawa M, Akizawa T, Kurokawa K. Is aplastic osteodystrophy a disease of malnutrition?. Curr Opin Nephrol Hypertens. 2000;9:363–367
  58. Kalantar-Zadeh K. Recent advances in understanding the malnutrition-inflammation-cachexia syndrome in chronic kidney disease patients: what is next?. Semin Dial. 2005;18:365–369
  59. Kovesdy CP, Kalantar-Zadeh K. Novel targets and new potential: developments in the treatment of inflammation in chronic kidney disease. Expert Opin Investig Drugs. 2008;17:451–467
  60. Kovesdy CP, Ahmadzadeh S, Anderson JE, et al. Obesity is associated with secondary hyperparathyroidism in men with moderate and severe chronic kidney disease. Clin J Am Soc Nephrol. 2007;2:1024–1029
  61. Panuccio V, Mallamaci F, Tripepi G, et al. Low parathyroid hormone and pentosidine in hemodialysis patients. Am J Kidney Dis. 2002;40:810–815
  62. Cantor T. Parathyroid hormone assay drift: an unappreciated problem in dialysis patient management. Semin Dial. 2005;18:359–364
  63. Melamed ML, Eustace JA, Plantinga LC, et al. Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: the CHOICE study. Nephrol Dial Transplant. 2008;23:1650–1658
  64. Regidor D, Kovesdy C, Mehrotra R, et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol. 2008;19:2193–2203
  65. Kalantar-Zadeh K, Kovesdy CP, Derose SF, et al. Racial and survival paradoxes in chronic kidney disease. Nat Clin Pract Nephrol. 2007;3:493–506
  66. Wolf M, Betancourt J, Chang Y, et al. Impact of activated vitamin D and race on survival among hemodialysis patients. J Am Soc Nephrol. 2008;19:1379–1388
  67. Rambod M, Kovesdy CP, Kalantar-Zadeh K. Malnutrition-Inflammation Score for risk stratification of patients with CKD: is it the promised gold standard?. Nat Clin Pract Nephrol. 2008;4:354–355
  68. Drechsler C, Krane V, Grootendorst DC, et al. The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrol Dial Transplant. 2009;24:3151–3157
  69. Chertow GM, Pupim LB, Block GA, et al. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol. 2007;2:898–905

 This study was supported by research grant DK61162 (for KKZ) from the National Institutes of Health, National Institute of Diabetes, Digestive and Kidney Disease, a research grant from DaVita, Inc (for KKZ), a philanthropist grant from Mr. Harold Simmons (for KKZ), and General Clinical Research Center (GCRC) grant M01-RR00425 from the National Centers for Research Resources, National Institutes of Health.

 Drs. Kalantar-Zadeh, Kovesdy, Sprague, and/or Budoff have received grants and/or honoraria from Shire, Amgen, Abbott, Genzyme, or Fresenus.

 The authors are thankful to Dr. Victor Goh, at Harbor-UCLA GCRC Core Laboratories, for the management of blood samples and measuring inflammatory markers, and to DaVita Clinical Research and DaVita dietitians for supporting the NIED Study in DaVita dialysis clinics in Los Angeles South Bay Area.

PII: S1051-2276(09)00284-2

doi: 10.1053/j.jrn.2009.10.006

Journal of Renal Nutrition
Volume 20, Issue 4 , Pages 243-254 , July 2010

Article Tools

* Image Usage & Resolution